Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB finds a way forward for Cimzia for RA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

UCB will not have to conduct an additional study to support a rheumatoid arthritis indication for Cimzia (certolizumab); the firm recently met with FDA to clarify the requirements needed for the expanded approval. Further analysis of existing data and a new safety update are required. UCB Chief Medical Officer Iris Loew-Friedrich said to anticipate the submission of their full response in the second quarter of this year. The firm received a "complete response" letter in January requesting more safety data on the tumor necrosis factor inhibitor, which is already approved for Crohn's disease (1"The Pink Sheet" DAILY, Jan. 5, 2009)

Related Content

Topics

UsernamePublicRestriction

Register

PS004086

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel